DOCSLIB.ORG

GREEN Dialkyl Hydroxysuccinates CIR EXPERT PANEL MEETING DECEMBER 12-13, 2011

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GREEN Dialkyl Hydroxysuccinates CIR EXPERT PANEL MEETING DECEMBER 12-13, 2011 GREEN Dialkyl Hydroxysuccinates CIR EXPERT PANEL MEETING DECEMBER 12-13, 2011 November 19, 2011 MEMORANDUM To: CIR Expert Panel and Liaisons From: Lillian C. Becker, M.S. Scientific Analyst and Writer Subject: Draft Report for dialkyl hydroxysuccinates and hydroxysuccinic acids ingredients used in cosmetics The Cosmetic Ingredient Review (CIR) announced the Scientific Literature Review (SLR) for dialkyl hydroxysuccinates in August, 2011. Comments and unpublished data have been received from industry and incorporated into the report. While the group is correctly named dialkyl hydroxysuccinates, there are a lot of malate and tartrate (salts and esters) ingredients are included because those are the names the dictionary gives to those particular mono- and dihydroxysuccinates. Diisostearyl Malate was the widely used (576 uses) lead ingredient that made this safety assessment a priority. The Panel should review the Draft Report and decide whether any additional data are needed in order to reach a safety conclusion. If additional data re needed, the Panel should issue an insufficient data announcement and identify the data needs. If no additional data are required, then the Panel should develop a tentative conclusion, with a rationale to be included in the discussion, and should issue a Tentative Report. Distributed for Comment Only -- Do Not Draft or Cite CIR Panel Book Page 1 Distributed for Comment Only -- Do Not Draft or Cite History of Malates and Tartrates (dialkyl hydroxysuccinates and hydroxysuccinic acids) June, 2011 - Added to the 2011 Priority List. August, 2011 – SLR announced. December, 2011 – The Panel views the Draft Report. CIR Panel Book Page 2 Distributed for Comment Only -- Do Not Draft or Cite Malate and tartrate Data Profile for Decemeber, 2011. Writer ‐ Lillian Becker Repeated dose Sensitizatio ADME Acute toxicity Irritation toxicity n Penetration Dermal Log K Use Oral Dermal Inhale Oral Dermal Inhale Irritation Ocular Animal Dermal Irr. Human Dermal Irr Animal Sensitization Human Sensitization toxicity Repro/Devel Genotoxicity Carcinogenicity Phototoxicity ow Malic Acid X X X X X X X x X Sodium Malate X X Tartaric Acid X X X X X X x X Calcium Tartrate Disodium Tartrate Potassium X Sodium Tartrate Potassium Tartrate Diisostearyl X X Malate Dibutyloctyl X Malate Di-C12-13 Alkyl Malate Diethylhexyl X X x x Malate Diisoamyl Malate Dioctyldodecyl Malate Di-C12-13 Alkyl X Tartrate Di-C14-15 Alkyl Tartrate Dimyristyl X Tartrate CIR Panel Book Page 3 Distributed for Comment Only -- Do Not Draft or Cite Search Strategy for Dialkyl Hydroxysuccinates Search terms Pubmed SciFinder “Diisostearyl Malate” OR “67763-18-2” OR “Butanedioic 487984 hits, all diisostearyl acid, 2-hydroxy-, 1,4-bis(16-methylheptadecyl) ester” OR malate. “diisostearyl malate” “Butanedioic acid, hydroxy-, bis(16-methylheptadecyl) – 1 hit ester (9CI)” OR “81230-05-9” OR “Butanedioic acid, 2- hydroxy-, 1,4-diisooctadecyl ester” OR “Cosmol 222” OR “Haimalate DIS” OR “Salacos 222” OR “Schercemol DISM” OR “Schercemol TN” February 2011 “Dibutyloctyl Malate” OR “399551-19-0” OR “Butanedioic 227511 hits, none for a acid, 2-hydroxy-, 1,4-bis(2-butyloctyl) ester” OR quoted term “Butanedioic acid, hydroxy-, bis(2-butyloctyl) ester (9CI)” February 2011 ”Di-C12-13 Alkyl Malate” No hits February 2011 ”Diethylhexyl Malate” OR ”56235-92-8” OR “Butanedioic 4601 hits, none for the acid, 2-hydroxy-, 1,4-bis(2-ethylhexyl) ester” OR quoted phrase “Butanedioic acid, hydroxy-, bis(2-ethylhexyl) ester (9CI)” OR “Dermol DOM” OR “Di(2-ethylhexyl) malate” OR “Malic acid diester with 2-ethylhexyl alcohol” OR “NSC 68868” February 2011 “Diisoamyl Malate” OR “Butanedioic acid, 2-hydroxy-, No hits 1,4-bis(3-methylbutyl) ester” OR “Butanedioic acid, hydroxy-, bis(3-methylbutyl) ester (9CI)” OR ”Isopentyl alcohol, malate (2:1)” OR ”Malic acid, diisopentyl ester (6CI, 7CI, 8CI) » OR « AI 3-20830” OR “Diisoamyl malate” OR “Diisopentyl malate” OR “ENT 20830” February 2011 ”Dioctyldodecyl Malate” No hits February 2011 “Malic Acid” OR “6915-15-7” OR “Hydroxybutanedioic 2030 hits. “Malic Acid” – 2030 acid” OR “hydroxysuccinic acid” hits. With irritation, February 2011 sensitization, phototoxicity, photoallergenicity, immunotoxicity, pharmacokinetic, tumorigenicity, carcinogenicity, genotoxicity, reproductive or developmental toxicity – 30 hits, 3 possibly useful. DL-Form“617-48-1” No hits February 2011 D-(+)-Form “636-61-3” No hits February 2011 L-(-)-Form 7715 hits. Seach for full “97-67-6” OR “Butanedioic acid, 2-hydroxy-, (2S)-“ OR terms found: "(-)-L-Malic “Butanedioic acid, hydroxy-, (2S)- (9CI)” OR acid", "(S)-Malic acid", "L-(-)- “Butanedioic acid, hydroxy-, (S)-“ OR “Malic acid, l- Malic acid", "L-Malic acid", (3CI)” OR “Malic acid, L- (8CI)” OR “(-)-(S)-Malic acid” "S-(-)-Malic acid". 2 hits. OR “(-)-Hydroxysuccinic acid” OR “(-)-L-Malic acid” OR None useful. “(-)-Malic acid” OR “(2S)-2-Hydroxybutanedioic acid” OR “(2S)-2-Hydroxysuccinic acid” OR “(2S)-Malic acid” OR “(S)-Malic acid” OR “Apple acid” OR “L-(-)-Malic acid” OR “L-Apple acid” OR “L-Malic acid” OR “NSC 9232” OR “S-(-)-Malic acid” OR “S-2-Hydroxybutanedioic acid” OR “498-37-3” OR “124501-05-9” OR “84781-39-5” OR “6294-10-6” February 2011 “Butanedioic acid, 2-hydroxy-, (2R)-“ OR “Butanedioic 2070 hits. Search of full terms acid, hydroxy-, (2R)- (9CI)” OR “Butanedioic acid, "D-(+)-Malic acid" OR "D- hydroxy-, (R)-“ OR “Malic acid, D- (8CI)” OR “(+)-Malic Malic acid" – 17 hits. None acid” OR “(2R)-2-Hydroxybutanedioic acid” OR “(2R)- useful. Malic acid” OR “(R)-(+)-Malic acid” OR “(R)-Malic acid” CIR Panel Book Page 4 Distributed for Comment Only -- Do Not Draft or Cite OR “D-(+)-2-Hydroxysuccinic acid” OR “D-(+)-Malic acid” OR “D-Malic acid” OR “15856-21-0” February 2011 “6915-15-7” OR “Butanedioic acid, 2-hydroxy-“ OR No hits “Butanedioic acid, hydroxy- (9CI)” OR “Malic acid (8CI)” OR “(&plusminus;)-Malic acid” OR “α- Hydroxysuccinic acid” OR “2-Hydroxybutanedioic acid” OR “2-Hydroxyethane-1,2-dicarboxylic acid” OR “2- Hydroxysuccinic acid” OR “Deoxytetraric acid” OR “dl- Malic acid” OR “DL-Malic acid” OR “E 296” OR “FDA 2018” OR “Hydroxybutanedioic acid” OR “Hydroxysuccinic acid” OR “Musashi-no-Ringosan” OR “Nanoveson M” OR “NSC 25941” OR “Pomalus Acid” OR “R,S(&plusminus;)-Malic acid” OR “879715-44-3” OR “623158-98-5” OR “617-48-1” OR “41308-42-3” February 2011 “Sodium Malate” OR “58214-38-3” OR “Butanedioic acid, 126468 hits. Sodium malate 2-hydroxy-, sodium salt (1:1)” OR “Butanedioic acid, – 15 hits. None useful. hydroxy-, monosodium salt (9CI)” OR “Monosodium malate” OR “57467-17-1” February 2011 “Di-C12-13 Alkyl Tartrate” OR “94095-06-4” OR No hits “Butanedioic acid, 2,3-dihydroxy- (2R,3R)-, C12-14- branched and linear” OR “alkyl esters” OR “Butanedioic acid, 2,3-dihydroxy- [R-(R*,R*)]-, C12-14-branched and linear alkyl esters” February 2011 “Di-C14-15 Alkyl Tartrate” OR “55568-47-3” OR 1 hit. Not useful. “Butanedioic acid, 2-hydroxy-, 1,4-ditetradecyl ester” OR “Butanedioic acid, hydroxy-, ditetradecyl ester (9CI)” OR ”Ditetradecyl malate” “Dimyristyl Tartrate” OR “94237-18-0” OR “Butanedioic No hits acid, 2,3-dihydroxy- (2R,3R)-, 1,4-ditetradecyl ester” OR “Butanedioic acid, 2,3-dihydroxy- (2R,3R)-, ditetradecyl ester (9CI)” OR “Butanedioic acid, 2,3-dihydroxy- [R- (R*,R*)]-, ditetradecyl ester” OR “Dimyristyl tartrate” February 2011 “Dimyristyl Tartrate” OR “L-Tartaric Acid” OR “87-69-4” 1323 hits for “L-Tartaric Acid” OR “(2R,3R)-2,3-Dihydroxybutanedioic acid” OR “tartaric OR “tartaric acid” OR “d- acid” OR “natural tartaric acid” OR “d-tartaric acid” OR tartaric acid”. With irritation, “(+)-tartaric acid” OR “dextrotartaric acid” OR “L-2,3- sensitization, phototoxicity, dihydroxybutanedioic acid” OR “d-α,β-dihydroxysuccinic photoallergenicity, acid” OR “Weinsäure” OR “Weinsteinsäure” immunotoxicity, February 2011 pharmacokinetic, tumorigenicity, carcinogenicity, genotoxicity, reproductive or developmental – 13 hits, none useful. Malic Acid (2) (8966) > refine "toxicology" Substance Identifier "67763-18-2; 81230-05-9; 399551- (280) > refine "Book Clinical 19-0; Di C12-13 Alkyl Malate; 56235-92-8; 1587-19-5; Trial Commentary Dioctyldodecyl Malate; 97-67-6; 617-48-1; 636-61-3; Conference Dissertation 6915-15-7; 94095-06-4; Di-C12-13 Alkyl Tartrate; Di- Journal Letter Report C14-15 Alkyl Tartrate; 94237-18-0; 87-69-4; 133-37-9; Review" (115) > refine "NOT 147-71-7; 3164-34-9; 868-18-8; 6106-24-7; 304-59-6; plant" (84) > keep 17 6381-59-5; 921-53-9 references (17) > remove 0 April, 2011 references (17) Malic Acid - Substance Identifier "67763-18-2; 81230-05- (19) > get references 9; 399551-19-0; Di C12-13 Alkyl Malate; 56235-92-8; (21243) > refine 1587-19-5; Dioctyldodecyl Malate; 97-67-6; 617-48-1; "Toxicology" (666) > refine 636-61-3; 6915-15-7; 94095-06-4; Di-C12-13 Alkyl "NOT plant" (480) > remove Tartrate; Di-C14-15 Alkyl Tartrate; 94237-18-0; 87-69-4; 16 references (464) > refine 133-37-9; 147-71-7; 3164-34-9; 868-18-8; 6106-24-7; "Dermal" (7) 304-59-6; 6381-59-5; 921-53-9 " April, 2011 "67763-18-2; 81230-05-9; 399551-19-0; Di C12-13 Alkyl ( (21243) > refine Malate; 56235-92-8; 1587-19-5; Dioctyldodecyl Malate; "Toxicology" (666) > refine CIR Panel Book Page 5 Distributed for Comment Only -- Do Not Draft or Cite 97-67-6; 617-48-1; 636-61-3; 6915-15-7; 94095-06-4; Di- "NOT plant" (480) > remove C12-13 Alkyl Tartrate; Di-C14-15 Alkyl Tartrate; 94237- 16 references (464) > refine 18-0; 87-69-4; 133-37-9; 147-71-7; 3164-34-9; 868-18-8; "ld50" (8) 6106-24-7; 304-59-6; 6381-59-5; 921-53-9 " April,
Load more

Recommended publications
  • Wednesday May 26, 1999
    5±26±99 Vol. 64 No. 101 Wednesday Pages 28333±28712 May 26, 1999 federal register 1 VerDate 06-MAY-99 21:29 May 25, 1999 Jkt 183247 PO 00000 Frm 00001 Fmt 4710 Sfmt 4710 E:\FR\FM\26MYWS.XXX pfrm03 PsN: 26MYWS II Federal Register / Vol. 64, No. 101 / Wednesday, May 26, 1999 The FEDERAL REGISTER is published daily, Monday through SUBSCRIPTIONS AND COPIES Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, PUBLIC Washington, DC 20408, under the Federal Register Act (44 U.S.C. Subscriptions: Ch. 15) and the regulations of the Administrative Committee of Paper or fiche 202±512±1800 the Federal Register (1 CFR Ch. I). The Superintendent of Assistance with public subscriptions 512±1806 Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition. General online information 202±512±1530; 1±888±293±6498 Single copies/back copies: The Federal Register provides a uniform system for making available to the public regulations and legal notices issued by Paper or fiche 512±1800 Federal agencies. These include Presidential proclamations and Assistance with public single copies 512±1803 Executive Orders, Federal agency documents having general FEDERAL AGENCIES applicability and legal effect, documents required to be published Subscriptions: by act of Congress, and other Federal agency documents of public Paper or fiche 523±5243 interest. Assistance with Federal agency subscriptions 523±5243 Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing.
    [Show full text]
  • Process for Preparing Ether-Carboxylic Acids and Salts
    Europaisches Patentamt 809 J) European Patent Office 00 Publication number: 0 355 A1 Office europeen des brevets EUROPEAN PATENT APPLICATION © Application number: 89115559.0 © mt. Ci.* C07C 59/305 , C11D 3/20 , C07C 51/367 @ Date of filing: 23.08.89 The title of the invention has been amended 0 Applicant: MONSANTO COMPANY (Guidelines for Examination in the EPO, A- III, 800 North Lindbergh Boulevard 7.3). St. Louis, MO 63167(US) © Priority: 24.08.88 US 236080 @ Inventor: Horng, Liou-Liang 12.12.88 US 282726 1731 Wishingwell Drive Creve Coeur Missouri 63146(US) @ Date of publication of application: Inventor: Griffith, Edward Jackson 28.02.90 Bulletin 90/09 310 Coventry Lane Manchester Missouri 63021 (US) © Designated Contracting States: Inventor: Jason, Mark E. AT BE CH DE ES FR GB GR IT LI LU NL SE 34 Ridge Point Drive Chesterfield Missouri 63017(US) © Representative: Dost, Wolfgang, Dr.rer.nat.,Dipl.-Chem. et al Patent- & Rechtsanwalte Bardehle . Pagenberg . Dost . Altenburg . Frohwitter . Geissler & Partner Galileiplatz 1 Postfach 86 06 20 D-8000 Munchen 86(DE) © Process for preparing ether-carboxylic acids and salts. © There is disclosed an improved process for preparing 1-hydroxy-3-oxa-1,2,4,5-pentane tetracarboxylic acid and 3,6-dioxa-1,2,4,5,7,8-octane hexacarboxylic acid wherein the reaction mixture has a solids concentration of above about 60%, by weight whereby the amount of by-product fumarate is reduced. < o 00 in LA CO a. LLJ Xerox Copy Centre EP 0 355 809 A1 CHEMICAL PROCESS This invention relates to an improved process for making ether carboxylic acids and more particularly to processes for making ether carboxylates prepared by a calcium ion catalyzed reaction in alkaline medium of maleic acid salt and a carboxylate salt containing a reactive hydroxyl group.
    [Show full text]
  • WO 2014/151200 A2 25 September 2014 (25.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/151200 A2 25 September 2014 (25.09.2014) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 38/04 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 14/025 197 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 13 March 2014 (13.03.2014) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/788,932 15 March 2013 (15.03.2013) kind of regional protection available): ARIPO (BW, GH, 61/826,738 23 May 2013 (23.05.2013) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant: SYNERGY PHARMACEUTICALS INC. TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, [US/US]; 420 Lexington Avenue, Suite 1609, New York, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, NY 10170 (US).
    [Show full text]
  • Tartaric Acid Handling 1 2 Identification of Petitioned Substance
    Tartaric Acid Handling 1 2 Identification of Petitioned Substance 3 Chemical Names: 14 4 2,3-dihydroxybutanedioic acid CAS Numbers: 5 L(+) tartaric acid: 87-69-4 6 Other Name: D(-) tartaric acid: 147-71-7 7 2,3-dihydroxysuccinic acid Mesotartaric acid: 147-73-9 8 Thearic acid Racemic acid: 133-37-9 9 Uvic acid 10 L(+) tartaric acid Other Codes: D(-) tartaric acid L(+) tartaric acid: 205-695-6 Mesotartaric acid D(-) tartaric acid: 201-766-0 Racemic acid Mesotartaric acid: 205-696-1 Racemic acid: 205-105-7 11 Trade Names: 12 None 1513 Characterization of Petitioned Substance 16 17 Composition of the Substance: 18 Tartaric acid [HOOCCH(OH)CH(OH)COOH; C4H6O6] is a four-carbon, organic acid with two OH groups 19 on the second and third carbon atoms, and two carboxylic acid (COOH) groups involving the first and 20 fourth carbons. The chemical structure of L(+) tartaric acid is shown below: 21 22 Source: Reusch, 1999 23 24 Tartaric acid exists in three distinct isomeric forms, as shown in the Fisher projection formulas below. Two 25 forms are chiral isomers, which means that the molecules are non-superimposable on their mirror images. 26 The form of tartaric acid found naturally in grapes and often produced synthetically for use in handling is 27 the L(+) tartaric acid isomer. This form is generally referred to as the ‘dextro form’ (Church and Blumberg, 28 1951). The D(-) form of tartaric acid is less common in nature and has almost no practical uses. The third 29 form is an achiral isomer, mesotartaric acid, that also can be manufactured (Reusch, 1999).
    [Show full text]
  • Halal Food Production
    HALAL FOOD PRODUCTION © 2004 by CRC Press LLC HALAL FOOD PRODUCTION Mian N. Riaz Muhammad M. Chaudry CRC PRESS Boca Raton London New York Washington, D.C. © 2004 by CRC Press LLC Library of Congress Cataloging-in-Publication Data Riaz, Mian N. Halal food production / Mian N. Riaz, Muhammad M. Chaudry. p. cm. Includes bibliographical references and index. ISBN 1-58716-029-3 (alk. paper) 1. Food industry and trade. I. Chaudry, Muhammad M. II. Title. TP370.R47 2003 297.5'76—dc22 2003055483 This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use. Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage or retrieval system, without prior permission in writing from the publisher. The consent of CRC Press LLC does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained in writing from CRC Press LLC for such copying. Direct all inquiries to CRC Press LLC, 2000 N.W. Corporate Blvd., Boca Raton, Florida 33431. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation, without intent to infringe.
    [Show full text]
  • Agenda Item 4D CX/FA 14/46/7 January 2014 JOINT FAO/WHO
    E Agenda Item 4d CX/FA 14/46/7 January 2014 JOINT FAO/WHO FOOD STANDARDS PROGRAMME CODEX COMMITTEE ON FOOD ADDITIVES Forty-Sixth Session Hong Kong, China, 17-21 March 2014 INFORMATION ON COMMERCIAL USE OF SELECTED FOOD ADDITIVES (REPLIES TO CL 2013/8-FA, PART B, POINT 4) Comments of Australia, Costa Rica, European Union and OIV AUSTRALIA Australia would like to submit the following information in regards to the commercial use of Dipotassium tartrate (INS 336(ii)), Monopotassium tartrate (INS 336 (i)) and Potassium bisulfite (INS228) as requested in Part B, Point 4 of CL 2013/8-FA: • Dipotassium tartrate (INS 336 (ii)) is used as an additive in winemaking in Australia. • Monopotassium tartrate (INS 336 (i)) is used as an additive in food, and also as a processing aid during winemaking in Australia. • Potassium bisulfite (INS 228) is used as an additive in winemaking in Australia. COSTA RICA Costa Rica want to extend appreciation for the opportunity for comment. Our experts have already reviewed the document however believe that Costa Rica has no information to provide. EUROPEAN UNION The European Union (EU) would like to inform that out of the additives listed only the following additives are permitted for use in foods in the EU in accordance with Annex II to Regulation (EC) No 1333/2008 provided they comply with the approved EU specifications (Regulation (EU) No 231/2012): Dipotassium tartrate (INS 336(ii)), monosodium tartrate (INS 335(i)), monopotassium tartrate (INS 336(i)), potassium adipates (INS 357), potassium malate (INS 351(ii)), sodium adipates (INS 356), potassium bisulfite (INS 228) and propane (INS 944).
    [Show full text]
  • Official Journal L 339 Volume 39 of the European Communities 30 December 1996
    ISSN 0378-6978 Official Journal L 339 Volume 39 of the European Communities 30 December 1996 English edition Legislation Contents I Acts whose publication is obligatory Commission Directive 96/77/EC of 2 December 1996 laying down specific purity criteria on food additives other than colours and sweeteners (M 1 Price : ECU 19,50 (') Text with EEA relevance . Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters , and are EN generally valid for a limited period . The titles of all other Acts are printed in bold type and preceded by an asterisk . 30 . 12 . 96 PEN Official Journal of the European Communities No L 339/ 1 I (Acts whose publication is obligatory) COMMISSION DIRECTIVE 96/77/EC of 2 December 1996 laying down specific purity criteria on food additives other than colours and sweeteners ( Text with EEA relevance ) THE COMMISSION OF THE EUROPEAN COMMUNITIES, human consumption ( 6 ), as amended by Directive 82/71 2/EEC ( 7 ); Flaving regard to the Treaty establishing the European Whereas Directives 65/66/EEC and 78/664/EEC should Community, be repealed accordingly ; Whereas it is necessary to take into acount the Having regard to Council Directive 89/107/EEC of specifications and analytical techniques for additives as 21 December 1988 on the approximation of the laws of set out in the Codex Alimentarius as drafted by the Joint the Member States concerning food additives authorized FAO/WHO Expert Committee on Food Additives for use in foodstuffs intended for human consumption
    [Show full text]
  • SIGHI Food Compatibility List
    Swiss Interest Group Histamine Intolerance (SIGHI) www.mastzellaktivierung.info | www.histaminintoleranz.ch Food Compatibility List Sort order: alphabetic, with categories. Updated: 2016-04-01 Compatibility list for diagnostic and thera- The specifications apply only for the pure foods peutic elimination diet at histaminosis (mast with no additives! For example, it applies only for cell activity syndrome MCAS, mastocytosis, pure natural cream, but not for cream with addi- tives. Additives are sometimes also hidden in sta- histamine intolerance), compiled from vari- ple foods where you would not expect them. ous sources and based on experience reports Therefore, please always read the list of ingredi- ents on the packaging. Compatibility scale Lactose Mechanisms affecting histamine metabolism 0 Free from lactose The list serves as a rough guide for the assess- 1 Low lactose content or may sometimes contain ment of the histamine potential, i.e. for the dose- lactose depending on the recipe dependent and partly individually different com- 2 Medium lactose content. Try out acceptable amount. patibility, which is influenced by various mecha- 3 High lactose content nisms. The reason for the incompatibility is spec- - No general statement possible ified in the list with the following letters: ? Insufficient or contradictory information H!: Highly perishable, rapid formation of Gluten histamine! 0 Gluten-free H: High histamine content 1 May contain gluten 3 Contains gluten A: Other biogenic amines - No general statement possible L : Liberators of mast cell mediators ? Insufficient or contradictory information (=histamine liberators) B: Blocker (=inhibitors) of diamine oxidase Histamine or of other histamine degrading enzymes 0 Well tolerated, no symptoms expected at usual in- take 1 Moderately compatible, minor symptoms, occa- sional consumption of small quantities is often tol- Not all foods are equally intolerable for all con- erated cerned, depending on the individual physical 2 Incompatible, significant symptoms at usual intake causes of histaminosis.
    [Show full text]
  • B COMMISSION REGULATION (EU) No 231/2012 Of
    02012R0231 — EN — 07.02.2018 — 017.001 — 1 This text is meant purely as a documentation tool and has no legal effect. The Union's institutions do not assume any liability for its contents. The authentic versions of the relevant acts, including their preambles, are those published in the Official Journal of the European Union and available in EUR-Lex. Those official texts are directly accessible through the links embedded in this document ►B COMMISSION REGULATION (EU) No 231/2012 of 9 March 2012 laying down specifications for food additives listed in Annexes II and III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council (Text with EEA relevance) (OJ L 83, 22.3.2012, p. 1) Amended by: Official Journal No page date ►M1 Commission Regulation (EU) No 1050/2012 of 8 November 2012 L 310 45 9.11.2012 ►M2 Commission Regulation (EU) No 25/2013 of 16 January 2013 L 13 1 17.1.2013 ►M3 Commission Regulation (EU) No 497/2013 of 29 May 2013 L 143 20 30.5.2013 ►M4 Commission Regulation (EU) No 724/2013 of 26 July 2013 L 202 11 27.7.2013 ►M5 Commission Regulation (EU) No 739/2013 of 30 July 2013 L 204 35 31.7.2013 ►M6 Commission Regulation (EU) No 816/2013 of 28 August 2013 L 230 1 29.8.2013 ►M7 Commission Regulation (EU) No 817/2013 of 28 August 2013 L 230 7 29.8.2013 ►M8 Commission Regulation (EU) No 1274/2013 of 6 December 2013 L 328 79 7.12.2013 ►M9 Commission Regulation (EU) No 264/2014 of 14 March 2014 L 76 22 15.3.2014 ►M10 Commission Regulation (EU) No 298/2014 of 21 March 2014 L 89 36 25.3.2014 ►M11 Commission Regulation
    [Show full text]
  • Evaluation of Certain Food Additives
    WHO Technical Report Series 1007 Evaluation of certain food additives Eighty-fourth report of the Joint FAO/WHO Expert Committee on Food Additives The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO’s constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the- art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization’s priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO’s Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation.
    [Show full text]
  • Metatartaric Acid (Tentative)
    0 out of 3 Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 84th meeting 2017 Metatartaric Acid (Tentative) This monograph was also published in: Compendium of Food Additive Specifications. Joint FAO/WHO Expert Committee on Food Additives (JECFA), 84th meeting 2017. FAO JECFA Monographs 20 © FAO/WHO 2017 1 out of 3 METATARTARIC ACID (TENTATIVE) New tentative specifications prepared at the 84th JECFA (2017) and published in FAO JECFA Monographs 20 (2017). The 84th JECFA concluded that metatartaric acid (when used in winemaking) is included in the group ADI of 0–30 mg/kg bw for L(+)-tartaric acid and its sodium, potassium, potassium–sodium salts, expressed as L(+)- tartaric acid. Information required on: • Characterization of the product (optical rotation, content of free tartaric acid, degree of esterification and molecular weight distribution) • IR spectrum (in a suitable medium) • Analysis results including above parameters from a minimum of 5 batches of products currently available in commerce along with QC data. The Committee requests that this information be submitted by December 2018. SYNONYMS INS No. 353 DEFINITION Metatartaric acid is a polydisperse polymer of tartaric acid with a degree of esterification above 32%. It is manufactured by heating L- tartaric acid from natural sources at temperatures of 150-170º under atmospheric or under a reduced pressure. The product contains di- tartaric monoester and diester, other polyester acids of variable chain length, as well as non-esterified tartaric acid. Chemical name Metatartaric acid C.A.S. number 56959-20-7/ 39469-81-3 Chemical formula (C4H4O5)n Assay Not less than 105% as total tartaric acid DESCRIPTION Crystalline or powder form with an off-white colour.
    [Show full text]
  • Re‐Evaluation of L(+)‐Tartaric Acid (E 334), Sodium Tartrates
    SCIENTIFIC OPINION ADOPTED: 29 January 2020 doi: 10.2903/j.efsa.2020.6030 Re-evaluation of L(+)-tartaric acid (E 334), sodium tartrates (E 335), potassium tartrates (E 336), potassium sodium tartrate (E 337) and calcium tartrate (E 354) as food additives EFSA Panel on Food Additives and Flavourings (FAF), Maged Younes, Gabriele Aquilina, Laurence Castle, Karl-Heinz Engel, Paul Fowler, Maria Jose Frutos Fernandez, Peter Furst,€ Rainer Gurtler,€ Ursula Gundert-Remy, Trine Husøy, Wim Mennes, Romina Shah, Ine Waalkens-Berendsen, Detlef Wol€ fle, Polly Boon, Paul Tobback, Matthew Wright, Jaime Aguilera, Ana Maria Rincon, Alexandra Tard and Peter Moldeus Abstract The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion on tartaric acid- tartrates (E 334-337, 354) when used as food additives. The Scientific Committee for Food (SCF) in 1990 established an acceptable daily intake (ADI) of 30 mg/kg body weight (bw) per day, for L(+)- tartaric acid and its potassium and sodium salts. The metabolism of L(+)-tartaric acid and its potassium sodium salt was shown to be species dependent, with a greater absorption in rats than in humans. No toxic effects, including nephrotoxicity, were observed in toxicological studies in which the L(+)-form was tested. There was no indication for a genotoxic potential of tartaric acid and its sodium and potassium salts. In a chronic study in rats, no indication for carcinogenicity of monosodium L(+)- tartrate was reported at the highest dose tested (3,100 mg/kg bw per day). The available studies for maternal or developmental toxicity did not report any relevant effects; no studies for reproductive toxicity were available; however, no effects on reproductive organs were observed in the chronic toxicity study.
    [Show full text]